Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Corynebacterium Infections | 1 | 2015 | 3 | 0.440 |
Why?
|
| Corynebacterium | 1 | 2015 | 10 | 0.440 |
Why?
|
| Cystitis | 1 | 2015 | 12 | 0.440 |
Why?
|
| Urinary Bladder | 1 | 2015 | 257 | 0.380 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2024 | 39 | 0.350 |
Why?
|
| Dyspepsia | 1 | 2008 | 9 | 0.270 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 888 | 0.270 |
Why?
|
| Helicobacter Infections | 1 | 2008 | 36 | 0.260 |
Why?
|
| Helicobacter pylori | 1 | 2008 | 36 | 0.260 |
Why?
|
| Fallopian Tubes | 1 | 2024 | 48 | 0.200 |
Why?
|
| Carcinoma in Situ | 1 | 2024 | 53 | 0.200 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 795 | 0.190 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2002 | 10 | 0.180 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2002 | 86 | 0.180 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1786 | 0.170 |
Why?
|
| Histiocytosis | 1 | 2001 | 7 | 0.170 |
Why?
|
| Retroperitoneal Space | 1 | 2001 | 41 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 201 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 305 | 0.160 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 1660 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2001 | 124 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 147 | 0.150 |
Why?
|
| Levonorgestrel | 1 | 2019 | 11 | 0.150 |
Why?
|
| Epithelioid Cells | 1 | 2016 | 13 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2001 | 339 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 1071 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 83 | 0.120 |
Why?
|
| Middle Aged | 14 | 2024 | 27540 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 360 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2363 | 0.110 |
Why?
|
| Sarcoma | 1 | 2016 | 220 | 0.110 |
Why?
|
| Cystoscopy | 1 | 2015 | 36 | 0.110 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2013 | 15 | 0.100 |
Why?
|
| Aged | 13 | 2019 | 20399 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 2562 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 1130 | 0.100 |
Why?
|
| Handwriting | 1 | 2012 | 6 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 41 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2023 | 505 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 226 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1992 | 50 | 0.090 |
Why?
|
| Humans | 22 | 2024 | 93138 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 531 | 0.090 |
Why?
|
| Biopsy | 3 | 2016 | 1172 | 0.080 |
Why?
|
| Female | 16 | 2024 | 48544 | 0.080 |
Why?
|
| Skin Diseases | 1 | 2012 | 173 | 0.080 |
Why?
|
| Adult | 10 | 2024 | 27850 | 0.080 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 21 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2010 | 36 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2002 | 165 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2705 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2007 | 3155 | 0.070 |
Why?
|
| Male | 10 | 2016 | 44357 | 0.070 |
Why?
|
| Inflammation | 1 | 2015 | 1049 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2012 | 373 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2008 | 9 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2007 | 570 | 0.070 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2007 | 3 | 0.070 |
Why?
|
| Apoptosis | 2 | 2019 | 1719 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 810 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 7039 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 1910 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 72 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 1171 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 232 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2007 | 121 | 0.060 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2006 | 5 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 16 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2003 | 2009 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 2 | 1999 | 337 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 63 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 346 | 0.060 |
Why?
|
| Precancerous Conditions | 2 | 2004 | 204 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 537 | 0.050 |
Why?
|
| Karyotype | 1 | 2024 | 34 | 0.050 |
Why?
|
| Cell Biology | 1 | 2004 | 15 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2024 | 68 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2004 | 179 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 226 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 106 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 93 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2002 | 83 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2002 | 180 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2008 | 4546 | 0.040 |
Why?
|
| Breast | 1 | 2003 | 302 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 621 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 348 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1704 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2004 | 301 | 0.040 |
Why?
|
| Crystallization | 1 | 2001 | 215 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 3891 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2016 | 351 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2002 | 753 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 710 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1999 | 72 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1732 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1999 | 159 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2001 | 679 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2002 | 550 | 0.030 |
Why?
|
| Adolescent | 2 | 2008 | 9550 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 1999 | 1769 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2016 | 14 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1171 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2016 | 47 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 161 | 0.030 |
Why?
|
| Prostatectomy | 1 | 1999 | 472 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 2543 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 292 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3815 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 291 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 212 | 0.030 |
Why?
|
| Tibia | 1 | 2013 | 79 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 401 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 308 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 9074 | 0.020 |
Why?
|
| Fibroma | 1 | 2010 | 30 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 350 | 0.020 |
Why?
|
| Logistic Models | 2 | 2008 | 1241 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 107 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 100 | 0.020 |
Why?
|
| Amniotic Band Syndrome | 1 | 1989 | 3 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1447 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1992 | 1518 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 111 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 66 | 0.020 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2007 | 12 | 0.020 |
Why?
|
| Breast Cyst | 1 | 2007 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 67 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 161 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 40 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 308 | 0.020 |
Why?
|
| Postmenopause | 1 | 2008 | 106 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 883 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2015 | 10132 | 0.010 |
Why?
|
| Carboplatin | 1 | 2006 | 321 | 0.010 |
Why?
|
| Chromogenic Compounds | 1 | 2004 | 5 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2006 | 478 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2004 | 73 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 303 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 146 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 66 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2002 | 25 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 78 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 194 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 108 | 0.010 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2003 | 116 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 317 | 0.010 |
Why?
|
| Mammography | 1 | 2003 | 494 | 0.010 |
Why?
|
| Mitosis | 1 | 1999 | 151 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 706 | 0.010 |
Why?
|
| Antisickling Agents | 1 | 1977 | 4 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 1 | 1977 | 17 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 1999 | 280 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 885 | 0.010 |
Why?
|
| Aspirin | 1 | 1977 | 164 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1997 | 404 | 0.010 |
Why?
|
| RNA | 1 | 1997 | 574 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 27965 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1989 | 229 | 0.000 |
Why?
|
| Radiography | 1 | 1989 | 750 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1989 | 2427 | 0.000 |
Why?
|
| Hemoglobin A | 1 | 1977 | 8 | 0.000 |
Why?
|
| Oxyhemoglobins | 1 | 1977 | 30 | 0.000 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1977 | 11 | 0.000 |
Why?
|
| Gels | 1 | 1977 | 51 | 0.000 |
Why?
|
| Acetylation | 1 | 1977 | 149 | 0.000 |
Why?
|
| Solubility | 1 | 1977 | 186 | 0.000 |
Why?
|
| Kinetics | 1 | 1977 | 1463 | 0.000 |
Why?
|